The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents

Biomaterials

Volumn 31, Issue 5, 2010, Pages 923-933

  Sahay, Gaurav ^a   Kim, Jong Oh ^a   Kabanov, Alexander V ^a,b   Bronich, Tatiana K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Caveolae; Drug delivery; Endocytosis; Nanomaterials; Nanoparticles; Nanoparticulate materials; Tight junctions

Indexed keywords

CAVEOLAE; ENDOCYTOSIS; NANO PARTICULATES; NANO-MATERIALS; TIGHT JUNCTIONS;

CALCIUM; CELL MEMBRANES; CHEMOTHERAPY; DRUG DELIVERY; DRUG INTERACTIONS; ETHYLENE; MICELLES; NANOPARTICLES; NANOSTRUCTURED MATERIALS; POLYETHYLENE OXIDES; POTENTIOMETRIC SENSORS;

CYTOLOGY;

COPOLYMER; DOXORUBICIN; NANOPARTICLE; POLY(ETHYLENE OXIDE)POLY(METHACRYLIC ACID)COPOLYMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM DEPLETION; CANCER CELL; CANCER CHEMOTHERAPY; CAVEOLA; CELL SPECIFICITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; EMBRYO; ENDOCYTOSIS; ENDOSOME; EPITHELIUM CELL; HUMAN; HUMAN CELL; IC 50; INTERNALIZATION; INTRACELLULAR TRANSPORT; IONIC STRENGTH; LYSOSOME; MICELLE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; SALT TOLERANCE; TIGHT JUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; NANOPARTICLES; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 70649114515     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.09.101     Document Type: Article

References (37)

1. Kabanov A.V., and Alakhov V.Y. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 19 1 (2002) 1-72
2. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., and Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2 12 (2007) 751-760
3. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2 5 (2003) 347-360
4. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4 2 (2005) 145-160
5. Otsuka H., Nagasaki Y., and Kataoka K. PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev 55 3 (2003) 403-419
6. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41 (2001) 189-207
7. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumor tropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46 12 (1986) 6387-6392
8. Gratton S.E., Ropp P.A., Pohlhaus P.D., Luft J.C., Madden V.J., Napier M.E., et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 105 33 (2008) 11613-11618
9. Sahay G., Batrakova E.V., and Kabanov A.V. Different internalization pathways of polymeric micelles and unimers and their effects on vesicular transport. Bioconjug Chem 19 10 (2008) 2023-2029
10. Bronich T.K., Keifer P.A., Shlyakhtenko L.S., and Kabanov A.V. Polymer micelle with cross-linked ionic core. J Am Chem Soc 127 23 (2005) 8236-8237
11. Batrakova E.V., Li S., Miller D.W., and Kabanov A.V. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 16 9 (1999) 1366-1372
12. Pourfarzaneh M., White G.W., Landon J., and Smith D.S. Cortisol directly determined in serum by fluoroimmunoassay with magnetizable solid phase. Clin Chem 26 6 (1980) 730-733
13. Woodle M.C., Collins L.R., Sponsler E., Kossovsky N., Papahadjopoulos D., and Martin F.J. Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential. Biophys J 61 4 (1992) 902-910
14. Ferrari M., Fornasiero M.C., and Isetta A.M. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods 131 2 (1990) 165-172
15. Gonzalez-Mariscal L., Lechuga S., and Garay E. Role of tight junctions in cell proliferation and cancer. Prog Histochem Cytochem 42 1 (2007) 1-57
16. Harush-Frenkel O., Altschuler Y., and Benita S. Nanoparticle-cell interactions: drug delivery implications. Crit Rev Ther Drug Carrier Syst 25 6 (2008) 485-544
17. Foerg C., Ziegler U., Fernandez-Carneado J., Giralt E., and Merkle H.P. Differentiation restricted endocytosis of cell penetrating peptides in MDCK cells corresponds with activities of Rho-GTPases. Pharm Res 24 4 (2007) 628-642
18. Carver L.A., and Schnitzer J.E. Caveolae: mining little caves for new cancer targets. Nat Rev Cancer 3 8 (2003) 571-581
19. Li L., Backer J., Wong A.S., Schwanke E.L., Stewart B.G., and Pasdar M. Bcl-2 expression decreases cadherin-mediated cell-cell adhesion. J Cell Sci 116 18 (2003) 3687-3700
20. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6 9 (2006) 688-701
21. Tsukita S., Furuse M., and Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2 4 (2001) 285-293
22. Salama N.N., Eddington N.D., and Fasano A. Tight junction modulation and its relationship to drug delivery. Adv Drug Deliv Rev 58 1 (2006) 15-28
23. Sweet D.M., Kolhatkar R.B., Ray A., Swaan P., and Ghandehari H. Transepithelial transport of PEGylated anionic poly(amidoamine) dendrimers: implications for oral drug delivery. J Control Release 138 1 (2009) 78-85
24. Kitchens K.M., Kolhatkar R.B., Swaan P.W., Eddington N.D., and Ghandehari H. Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: influence of size, charge and fluorescent labeling. Pharm Res 23 12 (2006) 2818-2826
25. Smith J., Wood E., and Dornish M. Effect of chitosan on epithelial cell tight junctions. Pharm Res 21 1 (2004) 43-49
26. Conner S.D., and Schmid S.L. Regulated portals of entry into the cell. Nature 422 6927 (2003) 37-44
27. Giepmans B.N., and van Ijzendoorn S.C. Epithelial cell-cell junctions and plasma membrane domains. Biochim Biophys Acta 1788 4 (2009) 820-831
28. Mosesson Y., Mills G.B., and Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 8 11 (2008) 835-850
29. Armstrong A., Brewer J., Newman C., Alakhov V., Pietrzynski G., Campbell S., et al. SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the oesophagus: a phase II window study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 24 (2006) 4080
30. Danson S., Ferry D., Alakhov V., Margison J., Kerr D., Jowle D., et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 90 (2004) 2085-2091
31. Bontha S., Kabanov A.V., and Bronich T.K. Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs. J Control Release 114 2 (2006) 163-174
32. Vogel U., Sandvig K., and van Deurs B. Expression of caveolin-1 and polarized formation of invaginated caveolae in Caco-2 and MDCK II cells. J Cell Sci 111 Pt 6 (1998) 825-832
33. Stamatovic S.M., Keep R.F., Wang M.M., Jankovic I., and Andjelkovic A.V. Caveolae-mediated internalization of occludin and claudin-5 during CCL2-induced tight junction remodeling in brain endothelial cells. J Biol Chem 284 28 (2009) 19053-19066
34. Frank P., Pavlides S., and Lisanti M. Caveolae and transcytosis in endothelial cells: role in atherosclerosis. Cell Tissue Res 335 1 (2009) 41-47
35. Rejman J., Bragonzi A., and Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther 12 3 (2005) 468-474
36. Kiss A.L., and Botos E. Endocytosis via caveolae: alternative pathway with distinct cellular compartments to avoid lysosomal degradation. J Cell Mol Med 13 7 (2009) 1228-1237
37. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 13 12 (1995) 527-537